{"id":2045,"date":"2022-03-02T10:17:19","date_gmt":"2022-03-02T10:17:19","guid":{"rendered":"http:\/\/demo2.folio3.com:8020\/?page_id=2045"},"modified":"2023-11-25T00:19:15","modified_gmt":"2023-11-25T00:19:15","slug":"qed-therapeutics-medical-care","status":"publish","type":"page","link":"https:\/\/growingstronger.org\/ur\/qed-therapeutics-medical-care\/","title":{"rendered":"QED Therapeutics &#8211; Medical Care"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"2045\" class=\"elementor elementor-2045\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-975cdeb elementor-section-full_width events-banner elementor-section-height-default elementor-section-height-default\" data-id=\"975cdeb\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8db195b\" data-id=\"8db195b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-6c076cd events-inner elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6c076cd\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-c126972\" data-id=\"c126972\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f05c11b events-banner elementor-widget elementor-widget-heading\" data-id=\"f05c11b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">QED Therapeutics<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-bbdb2e8 elementor-widget elementor-widget-image\" data-id=\"bbdb2e8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1920\" height=\"154\" src=\"https:\/\/growingstronger.org\/wp-content\/uploads\/2022\/02\/site-banner-bg.png\" class=\"attachment-full size-full wp-image-1308\" alt=\"site-banner-bg\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-47a8bac elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"47a8bac\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b1bde08\" data-id=\"b1bde08\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-61d0109 elementor-widget elementor-widget-text-editor\" data-id=\"61d0109\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"has-text-align-justify\"><span style=\"color: #3c475b;\"><a style=\"color: #3c475b;\" href=\"https:\/\/qedtx.com\/?utm_medium=chandlerproject&amp;utm_source=referral&amp;utm_campaign=advocacy\"><u>QED Therapeutics<\/u><\/a>, a\u00a0<a style=\"color: #3c475b;\" href=\"https:\/\/bridgebio.com\/\"><u>BridgeBio<\/u><\/a>\u00a0company, is dedicated to developing meaningful treatment options for those with\u00a0<a style=\"color: #3c475b;\" href=\"https:\/\/qedtx.com\/understanding-achondroplasia\/#what-is-achondroplasia-section\"><u>achondroplasia<\/u><\/a>. In August 2018, BridgeBio launched QED to focus on precision medicine for FGFR-driven diseases.\u00a0In October 2019, QED\u00a0<a style=\"color: #3c475b;\" href=\"https:\/\/bridgebio.com\/news\/qed-and-parent-company-bridgebio-announce-preclinical-data-supporting-tolerability-and-activity-of-low-dose-infigratinib-in-treating-achondroplasia\/\"><u>announced<\/u><\/a>\u00a0their preclinical data supporting tolerability and activity of low-dose Infigratinib in treating achondroplasia.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-246353d elementor-widget elementor-widget-spacer\" data-id=\"246353d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a882323 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a882323\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-7264a75\" data-id=\"7264a75\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-232f5ff elementor-widget elementor-widget-heading\" data-id=\"232f5ff\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-medium\">what is QED researching?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-36eba81 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"36eba81\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fbcfc8b\" data-id=\"fbcfc8b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-59a4ca9 elementor-widget elementor-widget-text-editor\" data-id=\"59a4ca9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>QED therapeutics is researching genetic variants that cause FGFR3 overactivity can lead to skeletal conditions such as achondroplasia. We are studying whether an investigational agent (infigratinib) has the potential to improve the irregular bone growth in achondroplasia by decreasing the overactivity of the FGFR3, thereby targeting the condition at its source. <i>Infigratinib is not currently approved for the treatment of achondroplasia by the U.S. Food and Drug Administration (FDA) or any other health authority. <\/i><span style=\"color: #3c475b;\"><u><a style=\"color: #3c475b;\" href=\"https:\/\/qedtx.com\/our-research\/\">Infigratinib is the only oral agent under investigation for achondroplasia and is currently being studied in the PROPEL clinical program.<\/a><\/u><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41b2639 elementor-widget elementor-widget-spacer\" data-id=\"41b2639\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6a7f090 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6a7f090\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-cb891d2\" data-id=\"cb891d2\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1902f62 elementor-widget elementor-widget-heading\" data-id=\"1902f62\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-medium\">qED in the Press<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-a36c419 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"a36c419\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-33d5fe7\" data-id=\"33d5fe7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-919cf5e elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"919cf5e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-announces-positive-feedback-from-the-u-s-fda-and-eu-ema-on-the-regulatory-path-for-a-pivotal-phase-3-trial-of-infigratinib-in-children-with-achondroplasia\/\">\n\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"far fa-newspaper\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia (September 9, 2023)<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-presents-updated-six-month-results-from-its-phase-2-cohort-5-trial-of-infigratinib-in-achondroplasia-at-the-endocrine-society-endo-2023-annual-conference\/\">\n\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"far fa-newspaper\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference (June 20, 2023)<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-present-updated-six-month-results-from-its-phase-2-cohort-5-study-of-infigratinib-in-achondroplasia-in-a-late-breaker-oral-presentation-at-the-endocrine-society-endo-2023-annual\/\">\n\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"far fa-newspaper\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference (June 8, 2023)<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/bridgebio.com\/news\/bridgebio-announces-positive-phase-2-cohort-5-results-of-infigratinib-in-achondroplasia\/\">\n\n\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"far fa-newspaper\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm\/year with No Treatment-related Adverse Events (March 6, 2023)<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<i aria-hidden=\"true\" class=\"far fa-newspaper\"><\/i>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">BridgeBio Pharma to Host Educational Roundtable with Esteemed Achondroplasia Expert on February 16, 2023 (February 13, 2023)<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-f441531 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"f441531\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-25b188c\" data-id=\"25b188c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d27aeb5 elementor-widget elementor-widget-spacer\" data-id=\"d27aeb5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d176b6c elementor-widget elementor-widget-text-editor\" data-id=\"d176b6c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"color: #3c475b;\"><b><a style=\"color: #3c475b;\" href=\"https:\/\/investor.bridgebio.com\/press-releases\"><u>Click here for more press releases from QED therapeutics\/BridgeBio<\/u><\/a><\/b><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-277dfdd elementor-widget elementor-widget-spacer\" data-id=\"277dfdd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"spacer.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-spacer\">\n\t\t\t<div class=\"elementor-spacer-inner\"><\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>QED Therapeutics QED Therapeutics, a\u00a0BridgeBio\u00a0company, is dedicated to developing meaningful treatment options for those with\u00a0achondroplasia. In August 2018, BridgeBio launched QED to focus on precision medicine for FGFR-driven diseases.\u00a0In October 2019, QED\u00a0announced\u00a0their preclinical data supporting tolerability and activity of low-dose Infigratinib in treating achondroplasia. what is QED researching? QED therapeutics is researching genetic variants that [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-2045","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/pages\/2045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/comments?post=2045"}],"version-history":[{"count":20,"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/pages\/2045\/revisions"}],"predecessor-version":[{"id":3781,"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/pages\/2045\/revisions\/3781"}],"wp:attachment":[{"href":"https:\/\/growingstronger.org\/ur\/wp-json\/wp\/v2\/media?parent=2045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}